Countries have now resumed use of the vaccine but regrettable damage has been done.
AstraZeneca says there have been 37 reports of blood clots among the more than 17 million people who have received the vaccine in Britain and continental Europe, adding: "This is much lower than would be expected to occur naturally ... and is similar across other licensed Covid-19 vaccines."
European officials said that they acted out of caution over safety and legal concerns; to be transparent; and protect public confidence.
But arguably lives were put at risk during a new surge in infections on the continent where half a million people have died. The clear and present danger is Covid-19.
Already-sluggish vaccine rollouts were affected. And trust in the vaccine was undercut. Credibility is coin for vaccines, especially in an ongoing crisis.
Trials and real-world data show that all the major vaccines are effective at preventing hospitalisations and deaths from the coronavirus. It is safer to have any one of the vaccines than not.
In New Zealand, although the AstraZeneca vaccine was one of four set to be used here, the Government has chosen to concentrate on the Pfizer/BioNTech shot for its rollout.
Using the same vaccine makes distribution easier. It's also easier to make the case for safety and overcome hesitancy through word of mouth and medical advice.
The blood-clot row is just the latest safety scare or problem to surround the AstraZeneca vaccine.
Last year, the single-shot AstraZeneca vaccine had initial advantages over the double-dose Pfizer/BioNTech. The AstraZeneca vaccine was cheaper and could be stored at normal fridge temperatures. It is the main vaccine in the Covax initiative to help poor countries.
But the vaccine got off on the wrong foot with confusing early test results. An error meant volunteers received a half-dose. There was also a lack of data on its use in older people.
The vaccine got caught up in the tense political aftermath of Brexit between Britain and the EU, and there have been controversies over supply orders and the hoarding of doses. More than half of the EU's 15 million AstraZeneca doses have been in storage.
Yet the vaccine has proved to be effective, especially in Britain where 11 million people have had it. Three-quarters of people aged over 80 now have Covid immunity there.
The major losers in all this appear to be the people needing a vaccine.